Biolinerx Stock Performance
| BLRX Stock | USD 4.40 0.11 2.44% |
On a scale of 0 to 100, BioLineRx holds a performance score of 8. The firm shows a Beta (market volatility) of 0.96, which signifies possible diversification benefits within a given portfolio. BioLineRx returns are very sensitive to returns on the market. As the market goes up or down, BioLineRx is expected to follow. Please check BioLineRx's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether BioLineRx's price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BioLineRx are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, BioLineRx showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.88) | Five Day Return (4.78) | Year To Date Return (57.14) | Ten Year Return (99.58) | All Time Return (99.87) |
Last Split Factor 1:40 | Dividend Date 2019-07-15 | Last Split Date 2025-01-30 |
1 | BioLineRx to Report First Quarter 2025 Results on May 27, 2025 BLRX Stock News | 05/20/2025 |
2 | BioLineRxs Buy Rating Reiterated at HC Wainwright | 05/28/2025 |
3 | BioLine Rx Upgraded to Buy by Jones Trading BLRX Stock News | 05/30/2025 |
4 | BioLineRx Soars 10.1 percent on Pipeline Progress - AInvest | 06/09/2025 |
5 | BioLineRx Approves Key Proposals at Annual Meeting - AInvest | 07/01/2025 |
6 | H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. After ASCO 2025 | 07/03/2025 |
7 | BioLineRx Shares Pass Above 200-Day Moving Average Time to Sell | 07/22/2025 |
| Begin Period Cash Flow | 4.3 M | |
| Total Cashflows From Investing Activities | 29.4 M |
BioLineRx | Build AI portfolio with BioLineRx Stock |
BioLineRx Relative Risk vs. Return Landscape
If you would invest 319.00 in BioLineRx on April 26, 2025 and sell it today you would earn a total of 121.00 from holding BioLineRx or generate 37.93% return on investment over 90 days. BioLineRx is currently generating 0.7724% in daily expected returns and assumes 7.4258% risk (volatility on return distribution) over the 90 days horizon. In different words, 66% of stocks are less volatile than BioLineRx, and 85% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioLineRx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioLineRx's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioLineRx, and traders can use it to determine the average amount a BioLineRx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.104
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BLRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.43 actual daily | 66 66% of assets are less volatile |
Expected Return
| 0.77 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 8 92% of assets perform better |
Based on monthly moving average BioLineRx is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioLineRx by adding it to a well-diversified portfolio.
BioLineRx Fundamentals Growth
BioLineRx Stock prices reflect investors' perceptions of the future prospects and financial health of BioLineRx, and BioLineRx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioLineRx Stock performance.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (9.38) % | ||||
| Current Valuation | 4.16 M | ||||
| Shares Outstanding | 3.72 M | ||||
| Price To Earning | (3.88) X | ||||
| Price To Book | 0.80 X | ||||
| Price To Sales | 0.75 X | ||||
| Revenue | 28.94 M | ||||
| Gross Profit | 14.5 M | ||||
| EBITDA | 3.92 M | ||||
| Net Income | (9.22 M) | ||||
| Cash And Equivalents | 43.15 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 15.04 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 4.58 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (43.87 M) | ||||
| Earnings Per Share | (6.00) X | ||||
| Market Capitalization | 16.78 M | ||||
| Total Asset | 38.91 M | ||||
| Retained Earnings | (399.83 M) | ||||
| Working Capital | 11.7 M | ||||
| Current Asset | 48.18 M | ||||
| Current Liabilities | 3.14 M | ||||
About BioLineRx Performance
Evaluating BioLineRx's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BioLineRx has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioLineRx has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 123.93 | 174.35 | |
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (0.87) | (0.91) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.69) | (0.72) |
Things to note about BioLineRx performance evaluation
Checking the ongoing alerts about BioLineRx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioLineRx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioLineRx is way too risky over 90 days horizon | |
| BioLineRx appears to be risky and price may revert if volatility continues | |
| BioLineRx has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 28.94 M. Net Loss for the year was (9.22 M) with profit before overhead, payroll, taxes, and interest of 14.5 M. | |
| BioLineRx currently holds about 43.15 M in cash with (43.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9. | |
| BioLineRx has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: BioLineRx Shares Pass Above 200-Day Moving Average Time to Sell |
- Analyzing BioLineRx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioLineRx's stock is overvalued or undervalued compared to its peers.
- Examining BioLineRx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioLineRx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioLineRx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioLineRx's stock. These opinions can provide insight into BioLineRx's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.